Skip to content

EBITDA margin at other companies

Baxter International logo
Baxter InternationalBAX
5.9%-6.2pp
DaVita logo
DaVitaDVA
20.3%-1.0pp
Medtronic logo
MedtronicMDT
25.9%-0.4pp
Haemonetics logo
HaemoneticsHAE
27.6%+6.1pp
CorMedix logo
CorMedixCRMD
54.6%
Teladoc Health logo
Teladoc HealthTDOC
6.1%+3.3pp

Other financials

Income statement

See full
Revenue$27.9M-6.3%
Gross profit$12.1M+9.3%
Operating income-$16.9M-3.2%
Net income-$19.0M+26.4%
EPS (diluted)-$1.03+71.9%

Balance sheet

See full
Cash & equivalents$30.6M-59.7%
Total debt$101.6M+3.5%
Total equity$111.7M-34.3%
Total assets$249.5M-17.2%

Cash flow

See full
Operating cash flow-$12.8M+50.0%
CapEx$65.0K-47.2%
Free cash flow-$12.9M+49.9%

Valuation

See full
Market cap$80.08M-77.6%
Enterprise value$151.13M-63.6%
P/S0.7×-2.3×

Profitability

See full
Gross margin40.6%+4.7pp
Operating margin-57.2%-12.9pp
Net margin-63.7%-16.7pp
FCF margin-29.1%-11.5pp

Returns & leverage

See full
Return on equity-53.2%-14.8pp
Debt / equity0.9×+0.3×
Current ratio6.3×-2.1×

Where this comes from

Calculated from Outset Medical, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Outset Medical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Outset Medical, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Outset Medical, Inc.'s EBITDA margin?
Outset Medical, Inc. (OM) reported EBITDA margin of -53.9% in Q1 2026.
How has Outset Medical, Inc.'s EBITDA margin changed year-over-year?
Outset Medical, Inc.'s EBITDA margin increased by 28.8% year-over-year, from -75.7% to -53.9%.
What is the long-term trend for Outset Medical, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), Outset Medical, Inc.'s EBITDA margin has grown at a -25.6% compound annual growth rate (CAGR), from -228.9% to -52.2%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.